Prurigo Nodularis: Recognizing, Diagnosing and Treating a Rare but Debilitating Disease
| Overview / Abstract: |
Prurigo Nodularis is a rare, chronic skin disorder that causes substantial patient burden, but is often overlooked or misdiagnosed and, until recently, had no medications approved by the US Food and Drug Administration. The interprofessional faculty share their real-world perspectives on the diagnosis and treatment of patients with prurigo nodularis to reduce patient burden of disease and improve health outcomes. Highlighting pathophysiologic mechanisms, the faculty discuss the evolving pharmacologic treatment of patients with prurigo nodularis that now includes dupilumab; they also review safety and efficacy data for medications in late-phase clinical investigation. Case studies are discussed to facilitate integration of key concepts into clinical practice. |
|
Expiration |
Aug 31, 2024 |
|
Discipline(s) |
Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physician CME, Physician Assistant CME |
|
Format |
Online |
|
Credits / Hours |
1.5 |
|
Accreditation |
AMA, ANCC,AAPA,CA-BRN, ACPE, IPCE |
|
Presenters / Authors / Faculty |
Jonathan Silverberg, MD, PhD, MPH |
|
Sponsors / Supporters / Grant Providers |
This activity is supported by educational grants from Galderma, and Sanofi and Regeneron Pharmaceuticals. |
|
Keywords / Search Terms |
Annenberg Center for Health Sciences at Eisenhower Diagnosis, Disease burden, Validated measures, Pathophysiologic targets, Evidence-based guidelines, Current treatment, Novel/Emerging treatment Free CE CME |
|